Efficacy and Safety of Oral Zavegepant in Migraine Prevention: A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study in Patients with Chronic Migraine.

This study explored the effectiveness and safety of oral zavegepant for chronic migraine prevention. It involved adults with a history of chronic migraines, experiencing many headache days each month. Participants received either zavegepant or a placebo for 12 weeks. The goal was to measure changes in the number of migraine days per month. Unfortunately, the study faced recruitment challenges and was stopped early. Out of 1753 individuals screened, 522 received treatment, and 411 completed the initial phase. The results showed that zavegepant may help reduce migraine frequency, but more research is needed. The findings could lead to new treatment options for chronic migraine sufferers. Overall, zavegepant presents a potential preventive approach for those dealing with frequent migraines. Further studies are necessary to confirm its effectiveness and safety in a larger population. Clinical relevance: This research indicates that zavegepant may offer new preventive options for patients suffering from chronic migraines.